Radioactive tracer could spot hidden breast cancer tumors
NCT ID NCT06745804
First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times
Summary
This early-phase trial is testing a new radioactive imaging agent called 68Ga-R10602 in 36 people with hormone receptor-positive breast cancer that has come back or spread. The agent is designed to light up tumors on PET/CT scans. The main goals are to check safety and see how well it finds cancer locations.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 68Ga-R10602 (a radioactive imaging agent injected into the body to find breast cancer tumors on PET/CT scans)
- What this could lead to
- If successful, this could provide a new way to see where hormone receptor-positive breast cancer has spread, helping doctors plan better treatment.
- What could go wrong
- This is a very early Phase 1 study with only 36 people, focused on safety and imaging ability, not treatment. The imaging agent may not work as hoped or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE RECEPTOR POSITIVE BREAST ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
UCLA Department of Medicine - Hematology/Oncology
Los Angeles, California, 90095, United States
-
University of Iowa
Iowa City, Iowa, 52242, United States
-
University of Michigan Medicine
Ann Arbor, Michigan, 48109, United States
-
University of Utah, Huntsman Cancer Institute
Salt Lake City, Utah, 844112, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test monitoring may be as good as scans for breast cancer patients
- New drug combo targets brain metastases in advanced cancers
- New drug cocktail shows promise in shrinking breast tumors before surgery
- Morning or evening? new study tests best time for cancer pill.
- New drug combo shows promise in Hard-to-Treat breast cancer
- New targeted therapy duo enters human trials for advanced breast cancer